2008

2008 INTERCEPT Conference Abstracts

 

Jump to Conference
ICEID ATACCC Platelets 2008 Meeting
SETS DGTI, ESFH, & SFTS ISH
ISBT Macao AABB ASH

 

International Conference on Emerging Infectious Diseases (ICEID)
March 16 - 19, 2008 | Atlanta, GA, USA

  • Sawyer L, Dupuis K, Kinsey J et al.  The INTERCEPT Blood System Inactivates Influenza H5N1 and Chikungunya Virus in Platelet Concentrates and Plasma.

Congreso Nacional de la Sociedad Espanola de Transfusion Sanguinea (SETS)
May 29 - 31, 2008 | Cadiz, Spain

  • Barbolla L, Algora M, Jurado M et al. Results from an Ongoing Hemovigilance Program Characterizing the Safety Profile of Platelet Transfusions Treated with Photochemical Treatment (INTERCEPT Blood System).
     
  • Castrillo Fernandez A, Castro Lareo A, Cid Fernandez J et al.  Evaluacion in vitro del Sistema INTERCEPT Para Plaquetas de Aferesis.
     
  • Yanez Izquierdo M, Gonzalez Fraile MI, Moya M et al.  Calidad en Pooles de Plaquetas Procesados con Tratemiento Fotoquimico (INTERCEPT Blood System).
     
  • Osselaer JC, Irsch J, Corash L. Treatment of Platelet Components for Pathogen Inactivation with the INTERCEPT Blood System Allows for 7-Day Storage: Impact on Organization and Economics in Blood Centers.
     
  • Padron F, Cazenave JP, Osselaer JC et al.  La Inactivacion de Patogenos en Plaquetas con INTERCEPT Blood System Tambien Previene el Desarrollo de Eich Asociada a Transfusion.
     
  • Cazenave JP, Osselaer JC, Waller C et al. Results from an Ongoing Hemovigilance Program Characterizing the Safety Profile of Plasma Transfusions Prepared With Photochemical Treatment (INTERCEPT Blood System).

XXXth International Congress of the International Society of Blood Transfusion (ISBT)
June 7–12, 2008 | Macao, China

  • Angelini-Tibert MF, Simon P, Currie C et al. Safety of Transfusing Split Platelet Components Prepared with Amotosalen Photochemical Treatment During a Chikungunya Virus Epidemic.Vox Sang 2008;95(Suppl 1):293.
     
  • Brussel A, Vandercappellen A, Lin L et al. Evaluation of Viral and Bacterial Inactivation in Platelet Concentrates Suspended In 100% Plasma Treated with the INTERCEPT Blood System.Vox Sang 2008;95(Suppl 1):301.
     
  • Cazenave JP, Waller C, Mendel I et al. Clinical Experience with Conventional Versus INTERCEPT Platelet Concentrates Transfused to all Patients During Two One-Year Periods: Reduction of Adverse Events with Equivalent Use of Blood Products.Vox Sang 2008;95(Suppl 1):305-306.
     
  • Cazenave JP, Wiesel ML, Mendel I et al. Intensive and Successful Transfusion of Pathogen Inactivated INTERCEPT Platelet Concentrates for Major Gynecological and Obstetrical Surgery in Glanzmann Thrombasthenia Type 1 with the Gypsy Mutation.  Vox Sang 2008;95(Suppl 1):306.
     
  • Cognasse F, Payrat JM, Corash L et al. Platelet Components Associated with Acute Transfusion Reactions: The Role of Platelet-Derived Soluble CD40-Ligand.  Vox Sang 2008;95(Suppl 1):51.
     
  • Corash L, Lin JS, Eiden J. Acute Lung Injury in Patients Receiving Repeated Platelet Transfusions. Vox Sang 2008;95(Suppl 1):300-301.
     
  • Kientz D, Isola H, Wiesel ML et al. Validation of Apheresis Concentrated Platelet Collection in Additive Solution with the MCS+ Device, for Pathogenic Inactivation with the Amotosalen Photochemical Process and UVA Light.Vox Sang 2008;95(Suppl 1):307.
     
  • Löf H, Knutson F. INTERCEPT Technology Reduces the Number of Side Effects after Platelet Transfusions.Vox Sang 2008;95(Suppl 1):286.
     
  • Henschler R, Wiesneth M, Pfeiffer HU et al. Generation of Double Dose Platelet Concentrates from Pooled Buffy-Coats for Pathogen Inactivation with INTERCEPT.Vox Sang 2008;95(Suppl 1):315.
     
  • Infanti L, Job S, Santoro M et al. Platelet Components Treated with Pathogen Inactivation using the INTERCEPT Blood System: Clinical Outcomes of the First Single-Centre Observational Trial in Switzerland. Vox Sang 2008;95(Suppl 1):289.
     
  • Osselaer JC, Doyen C, Defoin L et al. Impact of Amotosalen Photochemical Pathogen Inactivation Treatment (INTERCEPT Blood System) on the Response to Transfusion with 6- and 7-day Old Components.Vox Sang 2008;95(Suppl 1):291.
     
  • Osselaer JC, Doyen C, Defoin L et al. Impact of Photochemical Treatment of Platelet Components (INTERCEPT) on Platelet and RBC Component Use in a Diverse Patient Population during Three Years of Routine Practice.Vox Sang 2008;95(Suppl 1):284.
     
  • Osselaer JC, Doyen C, Defoin L et al. Impact of Photochemical Treatment of Platelet Components (INTERCEPT) on Platelet and RBC Component Use by Hematology Patients during Three Years of Routine Practice.Vox Sang 2008;95(Suppl 1):283.
     
  • Osselaer JC, Doyen C, Defoin L et al. Impact of Photochemical Treatment of Platelet Components (INTERCEPT) on Platelet and RBC Component Use by Oncology Patients during Three Years of Routine Practice.Vox Sang 2008;95(Suppl 1):300.
     
  • Rasongles P, Knutson F, Garraud O et al.  Results from an Ongoing Hemovigilance Program Utilizing an Electronic Data Capture System to Characterize the Safety Profile of Platelet Transfusions Prepared with Photochemical Treatment (INTERCEPT).Vox Sang 2008;95(Suppl 1):15.
     
  • Sawyer L, Mababangloob R, Patel N et al.  Pathogen Inactivation Achieved in Platelets Suspended in Plasma/SSP+ is Comparable to that Achieved in Platelets Suspended in Plasma/InterSol.Vox Sang 2008;95(Suppl 1):299-300.
     
  • Sawyer L, Pinkoski L, Deane M et al.  Storage of INTERCEPT-Treated Double Dose Platelets in Two Containers.Vox Sang 2008;95(Suppl 1):299.
     
  • Wagner SJ, Skripchenko A, Myrup A et al. The Effect of Amotosalen Photochemical Treatment (PCT) on the in Vitro Properties of Pooled, Individually-Leukoreduced, Whole Blood-Derived Platelets Stored in 100% Plasma.Vox Sang 2008;95(Suppl 1):263.
     
  • Dupuis K, Sawyer L. Inactivation of Influenza Virus Type A H5N1 in Platelets and Plasma by Treatment with the INTERCEPT Blood System.Vox Sang 2008;95(Suppl 1):301.
     
  • Steiert M, Castro E, Grellier P et al. Photochemical Inactivation with Amotosalen and UVA Light of Protozoan Parasites in Platelet and Plasma Components Using INTERCEPT Blood System.Vox Sang 2008;95(Suppl 1):291.
     
  • Cazenave JP, Osselaer JC, Waller C et al. Results from an Ongoing Hemovigilance Program Using an Electronic Data Capture System to Characterize the Safety Profile of Plasma Transfusions Prepared with the INTERCEPT Blood System.  Vox Sang 2008;95(Suppl 1):296.
     
  • Cazenave JP, Netzer P, Ravanat C et al. Thrombin Generation Capacity of Therapeutic Apheresis Plasma is Maintained Following Pathogen Inactivation with Photochemical Treatment (INTERCEPT Blood System).  Vox Sang 2008;95(Suppl 1):306.
     
  • de Valensart N, Rapaille A, Goossenaerts E et al. Analysis of the Impact of INTERCEPT Treatment on Fresh Plasma: Preservation of Coagulation Factors and Inhibitors Functional Activity.  Vox Sang 2008;95(Suppl 1):293.
     
  • Isola H, Kientz D, Bigey F et al. Implementation of Pathogen Inactivated Therapeutic Apheresis Plasma Following Photochemical Treatment with INTERCEPT by EFS-Alsace, a French Regional Blood Center.  Vox Sang 2008;95(Suppl 1):306-307.
     
  • Knutson F, Lejskog K, Ståhle M et al. The INTERCEPT Technology as Novel Approach for the Generation of Pathogen Inactivated Serum for the Culturing of Pancreatic Islets: Opportunities for Improvements.  Vox Sang 2008;95(Suppl 1):279.
     
  • Osselaer JC, Defoin L, Goffaux M et al. Routine Production of Three Plasma Products from One INTERCEPT Blood System Treatment.  Vox Sang 2008;95(Suppl 1):294.
     
  • Pinkoski L, Peterson T, Bayat J et al. Coagulation Factor Activity In INTERCEPT Plasma after Storage for 24 Months at -25° C.  Vox Sang 2008;95(Suppl 1):288.
     
  • Rapaille A, de Valensart N, Goossenaerts E et al. INTERCEPT Treatment for Pathogen Inactivation of Thawed Plasma: Coagulation Factors and Function are Preserved.  Vox Sang 2008;95(Suppl 1):292.
     
  • Cancelas JA, Dumont L, Herschel L et al.  A Randomized, Controlled, 2-Period Crossover Study of Recovery and Lifespan of Radiolabeled Autologous 35-Day-Old Red Blood Cells Preared with a Modified S-303 Treatment for Pathogen Inactivation.
     
  • Erickson AC, Schott MA, Lee VA et al.  Characterization of RBC Dehydration Induced by Alkaline pH and Glutathione.
     
  • Casenave JP.  European View About Pathogen Inactivation in Labile Blood Products.

Advanced Technology Applications for Combat Casualty Care (ATACCC)
August 11 - 13, 2008
| St. Pete Beach, FL, USA

  • Corash L, Lin JS, Eiden J.  Acute Lung Injury (ALI) in Patients Receiving Repeated Platelet Transfusions.

Joint Annual Congress of the German Society for Transfusion Medicine and Immunohaematology (DGTI) and the Interdisciplinary European Society for Haemapheresis and Haemotherapy (ESFH) in cooperation with the Societe Francaise de Transfusion Sanguine (SFTS)
September 16-19, 2008
| Dusseldorf, Germany

  • Henschler R, Pfeiffer HU, Wiesneth M et al. Development of a Double-Dose Platelet Concentrate from 7 Buffy Coats Using the INTERCEPT Procedure for Pathogen Inactivation. Transfus Med Hemother 2008;35(suppl 1):58.
     
  • Sawyer L, Pinkoski L, Deane M et al. Pathogen Inactivation of Double Dose Platelets with the INTERCEPT Dual Storage Container Set. Transfus Med Hemother 2008;35(suppl 1):60-61.
    [Poster PDF]
     
  • Witt V, Stiegler G, Höcker P et al. Pathogen Inactivated Platelet Concentrates in Children. Transfus Med Hemother 2008;35(S1):4-5.
     
  • Cazenave JP, Isola H, Pinkoski L et al. Coagulation Factor Activity in Whole Blood-Derived Plasma Treated with the INTERCEPT Blood System 18 Hours after Collection. Transfus Med Hemother 2008;35(suppl 1):60.
     
  • Mutfi NA, Erickson AC, Hanson D et al.  Optimization of S-303 Treatment Process for Pathogen Inactivation of Red Blood Cell Concentrates (RBC) Prepared in SAG-M.

American Association of Blood Banks Annual Meeting (AABB)
October 4-7, 2008 | Montréal, Canada

  • Al-Radwan R, Lin L, Slaedts M et al. Bacterial Contamination Residual Risks and Mitigations at the Kuwait Central Blood Bank. Transfusion 2008;48 (S1);108A-109A.
    [Poster PDF]
     
  • Cazenave JP, Waller C, Mendel I et al. Impact of Photochemical Treatment of Platelet Components (INTERCEPT ™) on Platelet and RBC Component Use by Hematology-Oncology Patients during Routine Practice. Transfusion 2008;48 (S1);36A.
     
  • Corash L, Lin JS, Eiden J. Serious Pulmonary Adverse Events & Acute Lung Injury Following Repeated Platelet Transfusions.Transfusion 2008;48 (S1);28A.
     
  • Osselaer JC, Doyen C, Defoin L et al. Response to Transfusion of 6- and 7-Day-Old Platelet Components Prepared with INTERCEPT Pathogen Inactivation System.Transfusion 2008;48 (S1);20A-21A.
     
  • Dupuis K, Sampson-Johannes A, Kinsey J et al. Inactivation of Influenza A H5N1 and Lymphocytic Choriomeningitis Virus (LCMV) by the INTERCEPT Blood System (IBS). Transfusion 2008;48 (S1);88A.
     
  • Cazenave JP, Osselaer J, Waller C et al. An Active Hemovigilance Program Utilizing an EDC System to Assess Safety of 2994 Plasma Transfusions Prepared with the INTERCEPT Blood System.  Transfusion 2008;48 (S1);29A.
     
  • de Valensart N, Rapaille A, Goossenaerts E et al. INTERCEPT Pathogen Inactivation for Plasma: Preservation of Coagulation Factors and Ease of Implementation.  Transfusion 2008;48 (S1);145A.
    [Poster PDF]
     
  • Erickson AC, Bayat J, Gao Y et al.  Evaluation of RBC Hydration After Treatment with S-303 Pathogen Inactivation at Varying Hematocrits (Hct).
     
  • Erickson AC, Schott MA, Castro G et al.  Evaluation of in vitro Quality of Stored RBC After Treatment with S-303 Pathogen Inactivation at Varying Hematocrit. 
     
  • Hanson D, Mababangloob R, Patel N.  Robustness of Bacteria and Virus Inactivation with S-303 Treatment in RBC Concentrates At Variable Hematocrit (Hct).

Platelets 2008 Meeting
October 15 - 18, 2008
| Woods Hole, MA, USA

  • Corash L, Lin JS, Eiden J.  Acute Lung Injury in Patiens Receiving Repeated Platelet Transfusions.
     
  • Osselaer JC, Doyen C, Defoin L et al.  Impact of Photochemical Treatment of Platelet  Components (INTERCEPT) on Platelet and RBC Component Use in a Diverse Patient Population During Three Years of Routine Practice.

International Society of Haematology XXXII (ISH)
October 19 - 23, 2008
| Bangkok, Thailand

  • Osselaer JC.  INTERCEPT voor Pathogeeninactivatie in Bloedplaatjes: 5 Jaar Ervaring in Mont-Godinne.

American Society of Hematology 50th Annual Meeting and Exposition (ASH)
December 6 - 9, 2008
| San Francisco, CA, USA

  • Cazenave JP, Ohlmann P, Isola H et al..  Photochemical Pathogen Inactivation Treatment of Human Plasma (amotosalen + UVA) Has No Major Impact on the Protein expression pattern Assessed by a 2-DIGE Proteomic Assay. Blood 2008;112(11):696.
    [View abstract]
     


 

Untitled Document